We’re delighted to announce that Broughton has launched an in-house toxicology services division to increase our capacity and introduce innovations to better assess the adverse effects of chemical...
Blog: Expansion of Toxicology team at Broughton
May 1, 2020 | Published by Chris Allen
Broughton announce expansion of Toxicology team directed by Yvonne Wilding.
Expansion of Toxicology team at Broughton
We’re delighted to welcome a number of additional toxicologists to the Broughton toxicology team, set up earlier this year.
This new team will build upon the support we provide to companies in the Electronic Nicotine Delivery Systems (ENDS) market by introducing innovations to better assess the adverse effects of chemical substances associated with e-cigarettes, across the global tobacco and nicotine market.
Meet the team
Most recent additions to the team include:
Yvonne Wilding: Director, Product Safety and Compliance
Yvonne is an experienced toxicologist with over 10 years’ broad regulatory experience and 20 years pharmaceutical drug development research and development leadership experience.
Having undertaken roles at GlaxoSmithKline and AstraZeneca, Yvonne is particularly skilled in the area of user safety and will apply her extensive experience and expertise in terms of interacting with regulatory authorities.
Her skills set also includes leading product development programs to ensure delivery of successful marketing applications and maximise the commercial opportunity for each product.
Dr Emmanuel Minet: Principal Scientist
As an experienced PhD Scientist with over 12 years’ experience in the field of tobacco products and novel nicotine delivery device risk characterization, Emmanuel formerly led Systems Toxicology and Compliance teams, and a multi-million pound research program, at British American Tobacco.
Emmanuel has authored and co-authored 35 peer-reviewed publications including papers in journals such as Nature and Scientific Reports.
Frazer Lowe: Principal Scientist
Frazer has over 18 years’ experience in toxicological testing, biomarkers and scientific strategy in a research and development environment.
Previous roles at British American Tobacco have involved taking a leading role in generating scientific strategy linking exposure to risk and developing new in vitro models in the fields of genetic toxicology and smoking-related disease. Frazer has also published over 20 papers in regulatory, experimental and disease-related scientific journals.
Djeren Simitdjioglu: Associate Toxicologist
Djeren is a Toxicology graduate with quality control experience within a major pharmaceutical company and experience as a pharmacist. Recently she was also involved in cellular toxicology research at the University of Birmingham.
Dr Anais Kahve: Toxicologist
Anais has experience of conducting human-health risk assessments, and particular areas of expertise include in vitro study design and validation, along with product development. She brings to the team rigorous analytical skills and the ability to interpret and assimilate complex data sets.
A team of toxicologists dedicated to ENDS
Our new toxicology services division offers an experienced team for delivering Quantitative Risk Assessments, and also regulatory in vitro Toxicity Testing. This includes investment into Customised-Off-The-Shelf (COTS) in silico (Q)SAR software aligned with the company’s in-house developed toxicology software application designed for toxicology data management compliant with data integrity regulations.
To discuss how our Toxicology Services team can help you understand and reduce the health risks of your ENDS products for a regulatory submission and advance a smoke free future, contact us to arrange a meeting.